DENOSUMAB (Xgeva®)
Alert: see other clinical indicationsClinical Indication
Prevention of skeletal related events in adults with bone metastases from solid tumours other than prostate
Comments
Xgeva® is the Reference (originator) product.
In LLR, Jubereq® 120 mg vial (denosumab biosimilar) is the preferred first-line option for prevention of skeletal related events in adults with bone metastases from solid tumours other than prostate; Xgeva® is used when a PFS is required.
Xgeva® remains available for patients intolerant to biosimilar alternatives.
Date of classification
May 2014
Orange
Shared Care Agreement. Higher risk medicines requiring significant regular monitoring which would be initiated by or at the recommendation of a specialist service which may include mental health services, secondary care, tertiary care, community providers, private providers and GPs with a specialist interest.